We work for you
West Michigan Rheumatology feels that it is an honor to be trusted to participate in your care. We take this confidence seriously, and promise to place your interests first. We will coordinate with your primary care team, do our best to integrate your care, and always seek out the highest quality resources to advance your health.
The West Michigan Rheumatology, PLLC, (WMR) established in 1991, is a growing, academically oriented rheumatology practice. Our founder was recruited to Grand Rapids to develop clinical services, rheumatology research and training programs. These are the same three shields that represent the Mayo mission. During this time we have closely aligned with and are faculty of the Michigan State University College of Human Medicine.
We serve West Michigan providing consultation and support to patients and their doctors. WMR was the first dedicated rheumatology consultative service for Butterworth and St. Mary’s Hospitals. We continue to provide inpatient consultations at St Mary’s Mercy Health.
Success has lead to growth and we have been incredibly fortunate to attract three other talented rheumatologists. In addition, we have developed a dedicated team of nurses, administrators and other professionals that support our mission. As an independent medical group, we work with but are distinct from regional health systems. This means we only work for you.
We want our work to make a difference in your life. We have networked and participate with national colleagues to develop new therapies for scleroderma, raynaud’s, rheumatoid and psoriatic arthritis, lupus, and myositis. It is amazing how we can now, in many cases, prevent joint damage, slow disease progression and sometimes induce remission. With WMR you can be confident you will receive care inspired by the most advanced research and practice.
Meet the Team
Richard Martin, M.D., M.A.
A native of New Jersey, earned his B.S. at the University of Michigan, and M.D. at Michigan State College of Human Medicine. He completed his residency in Primary Care Internal Medicine at the University of Rochester, New York, and a fellowship in Rheumatology at Mayo Clinic, Rochester, MN. Subsequently at Michigan State University, he earned a M.A. in Educational Psychology & Instructional Design and completed a 3 year NIH funded Clinical Epidemiology post-doctoral fellowship. He founded the West Michigan Rheumatology in 1991. His research has focused on evaluating emerging therapies for rheumatoid arthritis, raynauds and scleroderma as well as developing decision aids for patients considering biologics.
Andrew Head, M.D.
Originally from Cincinnati, OH, earned his B.S. degree at the University of Vermont, and M.D. at the University of Cincinnati. He completed his Internal Medicine residency at The Christ Hospital in Cincinnati, OH. His Rheumatology Fellowship was at the University of Tennessee – Memphis, where he also completed the CHORD fellowship in Health Services Research. He has been with WMR since 2004. He his initial research related to evaluating health disparities of rheumatic disease care. He has extended this to include evaluation of new treatments of rheumatoid, psoriatic arthritis, and gout as well as population studies evaluating determinants of patient choice of biologics.
Aaron Eggebeen, M.D.
A native of Grand Rapids and a graduate of Calvin College, MSU College of Human Medicine, and Michigan State University-Spectrum Health IM-Peds residency. He is board certified in pediatrics and internal medicine. He completed his rheumatology fellowship at the University of Pittsburg Medical Center. He has been with the WMR since 2007. While at the University of Pittsburg his research focused on antibody markers of polymyositis and dermatomyositis. He continued thread of research by coordinating with investigators at Pittsburg to lead the NIH funded Rituxan in Myositis Study at WMR. Currently he is the principle investigator at WMR for a first of kind clinical trial evaluating Rituxan to biosimilar molecule for the treatment of rheumatoid arthritis as well as a novel therapy for SLE.
Eric Slavin, M.D.
A native of Saginaw, MI, he earned his B.S. degree at the University of Michigan, and M.D. at the Ohio State University College of Medicine. He completed a residency in Internal Medicine at St Vincent Hospital Indianapolis, IN and a Fellowship in Rheumatology at the University of North Carolina, Chapel Hill. He joined WMR in 2015.